CID 2950007 as an inhibitor of Staphylococcus aureus infections

Cardinal Scholar

Show simple item record

dc.contributor.advisor McDowell, Susan A. England, Benjamin J. 2012-05-21T18:26:05Z 2013-12-26T20:17:45Z 2012-05-05 2012-05-05
dc.description.abstract Staphylococcus aureus (S. aureus) infections are deleterious to the body, sometimes leading to sepsis. Sepsis is a state of whole-body inflammation that occurs when a body begins fighting an infection. S. aureus is emerging as one of the more common sources of bacterial infection. Statins, a class of drugs meant to lower cholesterol, have had unexpected effects in the protection against S. aureus infections. However, concerns have been expressed over the depletion of mevalonate, which occurs with the use of statins. A compound called CID 2950007 has recently emerged as a possible adjunctive therapy for protection against S. aureus. CID 2950007 has a high specificity for binding to the GTPase CDC42, which plays a major role in S. aureus host cell invasion. Through several cytotoxicity assays, fluorescently-labeled bacteria, and western blot analysis, this research shows that CID 2950007 is non-toxic to cells and provides protection against S. aureus invasion.
dc.description.sponsorship Department of Biology
dc.subject.lcsh Rho GTPases -- Inhibitors.
dc.subject.lcsh Staphylococcus aureus infections -- Treatment.
dc.subject.lcsh Cell membranes -- Physiology.
dc.title CID 2950007 as an inhibitor of Staphylococcus aureus infections en_US Thesis (M.S.) 2012-05-22

Files in this item

This item appears in the following Collection(s)

  • Master's Theses [5510]
    Master's theses submitted to the Graduate School by Ball State University master's degree candidates in partial fulfillment of degree requirements.

Show simple item record

Search Cardinal Scholar


My Account